CERo Therapeutics (NASDAQ:CERO) & Tourmaline Bio (NASDAQ:TRML) Financial Review

Tourmaline Bio (NASDAQ:TRML) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Volatility and Risk

Tourmaline Bio has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of -0.44, suggesting that its stock price is 144% less volatile than the S&P 500.

Profitability

This table compares Tourmaline Bio and CERo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tourmaline Bio	N/A	-19.56%	-18.91%
CERo Therapeutics	N/A	N/A	-23.86%

Institutional & Insider Ownership

91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are owned by institutional investors. 11.0% of Tourmaline Bio shares are owned by company insiders. Comparatively, 15.8% of CERo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Tourmaline Bio and CERo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tourmaline Bio	0	0	6	0	3.00
CERo Therapeutics	0	0	0	0	N/A

Tourmaline Bio currently has a consensus price target of $61.80, suggesting a potential upside of 304.72%. Given Tourmaline Bio’s higher probable upside, equities research analysts plainly believe Tourmaline Bio is more favorable than CERo Therapeutics.

Valuation & Earnings

This table compares Tourmaline Bio and CERo Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tourmaline Bio	N/A	N/A	-$42.12 million	($6.50)	-2.35
CERo Therapeutics	N/A	N/A	-$2.54 million	N/A	N/A

Summary

Tourmaline Bio beats CERo Therapeutics on 5 of the 8 factors compared between the two stocks.

About Tourmaline Bio

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.